Minoxidil vs MK-677
FDA Approved vs Well Studied
monitor Mechanism-based · 51% Both Minoxidil and MK-677 can raise blood pressure. Monitor BP regularly and consider adding cardiovascular support (cardarine, telmisartan, or similar).
Molecular Data
Minoxidil MK-677
Weight 209.25 Da 624.77 Da
Half-life ~4 hours (oral); topical effects persist significantly longer due to local tissue retention ~24 hours
Type Synthetic pyrimidine derivative (6-amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine) Non-peptide ghrelin receptor agonist
Key Benefits
Minoxidil
01 FDA-approved for androgenetic alopecia with decades of clinical evidence
02 Stimulates new hair growth and increases hair follicle size independent of androgen pathways
03 Available over the counter as a topical treatment without a prescription
04 Effective in both men and women for pattern hair loss
05 Low-dose oral formulation offers a convenient once-daily alternative to twice-daily topical application
06 Synergistic with finasteride and dutasteride for a multi-mechanism approach to hair loss
07 Extends the anagen (growth) phase and shortens the telogen (resting) phase of the hair cycle
MK-677
01 97% increase in 24-hour growth hormone secretion
02 40-72% elevation in IGF-1 levels
03 Enhanced sleep quality with improved REM patterns
04 Preferential lean tissue gains of 1.1-2.7kg over 8-12 months
05 15% basal metabolic rate increase within 2 weeks
06 Oral administration (no injections required)
Side Effects
Minoxidil
Scalp irritation, dryness, or flaking (topical, especially solution formulations containing propylene glycol)
Initial shedding phase during the first 1-3 months of treatment
Hypertrichosis (unwanted facial and body hair growth, more common with oral administration)
Fluid retention and mild peripheral edema (oral)
Mild dizziness or lightheadedness upon standing (oral, due to vasodilation)
MK-677
Appetite stimulation (>50% of users)
Water retention (30-40%)
Lethargy (20-30%)
Fasting glucose elevation (5-15mg/dL)
Note on testosterone suppression: at doses up to 20 mg daily, MK-677 is unlikely to cause significant testosterone suppression on its own. Above 20 mg daily, the likelihood of suppression and other side effects (insulin resistance, water retention, lethargy) increases. The case report documenting 85.7% testosterone suppression involved co-administration with LGD-4033, a SARM known to be profoundly suppressive, making the SARM the likely primary driver of that suppression.
Contraindications
Known hypersensitivity to minoxidil or any component of the formulation
Pheochromocytoma (minoxidil may stimulate catecholamine release)
Significant cardiovascular disease, including history of pericardial effusion or congestive heart failure
Concurrent use of potent antihypertensive medications without physician supervision (risk of additive hypotension)
Pregnancy and breastfeeding (Category C; oral minoxidil has shown evidence of fetal harm in animal studies)
Heart disease or congestive heart failure
Diabetes or pre-diabetes
Active cancer
Severe cardiovascular disease
Pregnancy or breastfeeding
Research Evidence
Minoxidil MK-677
Status FDA Approved Well Studied
References 5 studies 7 studies
Latest — July 2024
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.